Article Text

Download PDFPDF
Tirapazamine plus cisplatin in advanced or recurrent carcinoma of the uterine cervix: a Southwest Oncology Group study
  1. H. O. Smith*,
  2. C. S. Jiang,
  3. G. R. Weiss,
  4. III A. V. Hallum§,
  5. P. Y. Liu,
  6. III W. R. Robinson,
  7. P. C. Cheng,
  8. S. A. Scudder,
  9. M. Markman# and
  10. D. S. Alberts§
  1. *University of New Mexico Health Sciences Center, Albuquerque, New Mexico
  2. Southwest Oncology Group Statistical Center, Seattle, Washington
  3. University of Texas Health Science Center, San Antonio, Texas
  4. §University of Arizona Cancer Center, Tucson, Arizona
  5. Tulane University, New Orleans, Louisiana
  6. University of California, Davis, Sacramento, California
  7. #Cleveland Clinic Foundation, Cleveland, Ohio
  1. Address correspondence and reprint requests to: Harriet O. Smith, MD, Department of Obstetrics and Gynecology, 1 University of New Mexico, MSC 10 5580, Albuquerque, NM 87131-5286. Email: hsmith{at} Address reprint requests to: Southwest Oncology Group (59717), Operations Office, 14980 Omicron Drive, San Antonio, Texas 78245-3217. Email: pubs{at}


The objective of this study was to determine objective response and overall survival (OS) and progression-free survival (PFS) following cisplatin plus tirapazamine treatment in eligible consenting patients with metastatic or recurrent squamous or adenosquamous carcinoma of the cervix. Treatment consisted of intravenous tirapazamine, 260 mg/m2, followed by cisplatin, 75 mg/m2, every 21 days for six cycles. Of 56 registered cases, 52 were evaluable for toxicity. There were six grade 4 toxicities (anemia [three], dyspnea [one], neutropenia/granulocytopenia [one], and dehydration [one]). Fifty-three patients were evaluable for response, OS, and PFS. The 6-month OS rate was 56.6% (95% CI 43.3–69.9%). The objective response rate was 32.1% (4 complete [2 confirmed and 2 unconfirmed] and 13 partial [8 confirmed and 5 unconfirmed]). Higher response rates (16/34 [47.1%] vs 1/19 [5.3%], P = 0.0018) were observed in patients who had not previously received radiation-sensitizing chemotherapy, as were OS and PFS (13.9 vs 4.0 months, P < 0.0001; 5.3 vs 1.8 months, P = 0.01). The OS was considered too low to warrant further testing in this disease setting. Despite this, tirapazamine plus cisplatin was active in patients who had not received cisplatin previously. Prior use of radiosensitizing chemotherapy impacted response and survival significantly and should be considered in future clinical trials.

  • cervical carcinoma
  • chemotherapy
  • cisplatin
  • tirapazamine

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.


  • W.R. Robinson is presently at Harrington Cancer Center, Amarillo, Texas. Presented at the 35th Annual Meeting of the Society of Gynecologic Oncologists, San Diego Marriott Hotel and Marina, February 7–11, 2004.